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Schizophrenia is a non-curable mental disturbance which normally affects young adults characterized by a wide spectrum of symptoms ranging from hallucinations and delusions -classified as positive symptoms -to impairments in social interaction and anhedonia -classified as negative symptoms.
Additionally, cognitive impairments are present in the course of this disorder which can potentially affect patients' abilities of studying or working [1] . Schizophrenia affects approximately 30 million people worldwide and is likely to be caused by abnormal gene function since the neurodevelopment, triggered by environmental factors [2] . No laboratorial test is available for detecting schizophrenia.
About 12 years ago, large-scale detection methods started being used in order to increase the knowledge about the pathobiology of schizophrenia and also to reveal potential biomarkers. Firstly, DNA microarray studies were performed in several brain regions of postmortem tissue from schizophrenia patients and controls [3] , mainly revealing the differential expression of genes related to synaptic transmission and energy metabolism across multiple cell types. At the same time, proteomic analyses started being employed in postmortem brains [4] , but largely explored only a few years later [5] . The main appeal Proteomic studies in schizophrenia have followed two main objectives: 1) better characterization of the molecular bases of schizophrenia, which seems to go beyond the hypotheses proposed so far; 2) the necessity of revealing biomarkers for prognosis, successful treatment and patients' stratification.
Proteomic studies were conducted in several tissues from schizophrenia patients such as brain tissue [6] , pituitary [7] , cerebrospinal fluid [8, 9] , liver [10] , peripheral blood mononuclear cells [11] , fibroblasts [12] and serum [13, 14] [14] were combined to the DiscoveryMAP multiplex immunoassay, generating a laboratorial test which is supposedly able of distinguishing first-onset drug-naive schizophrenia patients from control subjects [15] . The product marketed as VeriPsych™, is defined as an "aid [to] psychiatrists in the diagnosis of recent-onset schizophrenia" and "it is not intended to provide a definitive diagnosis of schizophrenia"
(http://www.veripsych.com). [17] .
In order to approximate bench to bedside, there are some basic tasks to be performed. in detailed molecular mechanisms [25, 26] .
For instance, the role of astrocytes [27] and oligodendrocytes [28] must be explored for understanding their role in schizophrenia.
Understanding the dynamics of each cell type in the pathogenesis maybe lead to more effective interventions. Translational Neuroscience
